Oncology Clinical Pathways Spotlight
This week in health care trends, our oncology clinical pathways spotlight includes: the trouble with clinical pathways according to ASCO, why providing drugs in multiple vial sizes could actually save money, and one another reflects on VP Biden’s speech at ASCO.
In a policy statement, ASCO argues that “Because payers and for-profit companies create and distribute [clinical] pathways and because many are tailored to different agendas, the process is laden with inadequacies, conflicts of interest and “unsustainable” administrative burden”.
In this article, HealthAffairs discusses the merits of offering cancer drugs in multiple vial sizes as well as the effect on overall finances: “the added cost of manufacturing and distributing another smaller vial size would be offset by the savings manufacturers would enjoy from having to make less of the drug.”
This author reflects on Vice President Biden’s speech at the recent ASCO Annual Meeting and asks, “The use of guidelines and pathways is often encouraged as a sign of following evidence-based medicine, but do they really go far enough?”
Siemens Healthineers’ New CT and MRI Technologies to Aid Research Across Various Common Clinical Pathways
The research outlined in this article “will look to challenge current practice within common clinical pathways and, through the use of Siemens Healthineers technology, demonstrate how imaging can be used more proactively and effectively”.
The articles above are from our dedicated Oncology Clinical Pathways e-magazine. Follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)